Interstitial lung disease

 
The IPF Pipeline is Set to Deliver: The 3 Top Contenders
September 10, 2025

Nerandomilast, with a PDUFA date of Q4 2025, leads the potential breakthrough therapies, with inhaled treprostinil and admilparant advancing quickly behind.

Nerandomilast Meets Primary Endpoint in Phase III FIBRONEER-ILD Trial in Progressive Pulmonary Fibrosis
February 11, 2025

Topline data announced by Boehringer Ingelheim for the PDE4B inhibitor showed a statistically significant absolute change from baseline in FVC at week 52 vs placebo.